Literature DB >> 9008273

A semiquantitative assay for CD8+ T-cell-mediated suppression of human immunodeficiency virus type 1 infection.

Y Chen1, C Rinaldo, P Gupta.   

Abstract

A reproducible, semiquantitative assay was developed to measure the level of the anti-human immunodeficiency virus type 1 (anti-HIV-1) suppressive activity of CD8+ T cells. The assay had a wide dynamic range and could be applied to a relatively small number of fresh and cryopreserved peripheral blood mononuclear cells and purified CD8+ T cells. The suppressive activity was not due to cytolytic activity and was not major histocompatibility complex class I restricted. Suppression of HIV-1 infection by CD8+ T cells was consistently demonstrable with both endogenously infected autologous CD4+ T cells and exogenously infected allogeneic CD4+ T cells. This assay can be used to monitor the level of antiviral activity of CD8+ T cells in a retrospective and prospective manner in studies of the natural history of HIV-1 infection and of subjects receiving anti-HIV-1 therapy and vaccines.

Entities:  

Mesh:

Year:  1997        PMID: 9008273      PMCID: PMC170467          DOI: 10.1128/cdli.4.1.4-10.1997

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  22 in total

1.  CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual.

Authors:  C E Mackewicz; H W Ortega; J A Levy
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

2.  Suppression of simian immunodeficiency virus replication in vitro by CD8+ lymphocytes.

Authors:  M Kannagi; L V Chalifoux; C I Lord; N L Letvin
Journal:  J Immunol       Date:  1988-04-01       Impact factor: 5.422

3.  CD8+ T cells from HIV-1-infected individuals inhibit acute infection by human and primate immunodeficiency viruses.

Authors:  C M Walker; G A Thomson-Honnebier; F C Hsueh; A L Erickson; L Z Pan; J A Levy
Journal:  Cell Immunol       Date:  1991-10-15       Impact factor: 4.868

4.  Acquired immunodeficiency syndrome (AIDS)-free time after human immunodeficiency virus type 1 (HIV-1) seroconversion in homosexual men. Multicenter AIDS Cohort Study Group.

Authors:  A Muñoz; M C Wang; S Bass; J M Taylor; L A Kingsley; J S Chmiel; B F Polk
Journal:  Am J Epidemiol       Date:  1989-09       Impact factor: 4.897

5.  Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8+ cells involves a noncytotoxic mechanism.

Authors:  C M Walker; A L Erickson; F C Hsueh; J A Levy
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

6.  A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication.

Authors:  C M Walker; J A Levy
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

7.  Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins.

Authors:  Y Riviere; F Tanneau-Salvadori; A Regnault; O Lopez; P Sansonetti; B Guy; M P Kieny; J J Fournel; L Montagnier
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

8.  Anti-HIV type 1 cytotoxic T lymphocyte effector activity and disease progression in the first 8 years of HIV type 1 infection of homosexual men.

Authors:  C R Rinaldo; L A Beltz; X L Huang; P Gupta; Z Fan; D J Torpey
Journal:  AIDS Res Hum Retroviruses       Date:  1995-04       Impact factor: 2.205

9.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

10.  CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor.

Authors:  J E Brinchmann; G Gaudernack; F Vartdal
Journal:  J Immunol       Date:  1990-04-15       Impact factor: 5.422

View more
  7 in total

1.  Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture.

Authors:  Phalguni Gupta; Deena Ratner; Ming Ding; Bruce Patterson; Lisa C Rohan; Todd A Reinhart; Velpandi Ayyavoo; Xioli Huang; Dorothy L Patton; Bharat Ramratnam; Alexander M Cole
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-15       Impact factor: 3.731

2.  Dendritic cells restore CD8+ T cell reactivity to autologous HIV-1.

Authors:  Kellie N Smith; Robbie B Mailliard; Brendan B Larsen; Kim Wong; Phalguni Gupta; James I Mullins; Charles R Rinaldo
Journal:  J Virol       Date:  2014-06-18       Impact factor: 5.103

3.  ADAR1 is a novel multi targeted anti-HIV-1 cellular protein.

Authors:  Nabanita Biswas; Tianyi Wang; Ming Ding; Ashwin Tumne; Yue Chen; Qingde Wang; Phalguni Gupta
Journal:  Virology       Date:  2011-11-21       Impact factor: 3.616

4.  Noncytolytic inhibition of X4 virus by bulk CD8(+) cells from human immunodeficiency virus type 1 (HIV-1)-infected persons and HIV-1-specific cytotoxic T lymphocytes is not mediated by beta-chemokines.

Authors:  R Geiben-Lynn; M Kursar; N V Brown; E L Kerr; A D Luster; B D Walker
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Noncytotoxic suppression of human immunodeficiency virus type 1 transcription by exosomes secreted from CD8+ T cells.

Authors:  Ashwin Tumne; Varsha Shridhar Prasad; Yue Chen; Donna B Stolz; Kunal Saha; Deena M Ratner; Ming Ding; Simon C Watkins; Phalguni Gupta
Journal:  J Virol       Date:  2009-02-04       Impact factor: 5.103

6.  Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T Cells.

Authors:  Kellie N Smith; Robbie B Mailliard; Paolo A Piazza; Will Fischer; Bette T Korber; Ronald J Fecek; Deena Ratner; Phalguni Gupta; James I Mullins; Charles R Rinaldo
Journal:  mBio       Date:  2016-05-31       Impact factor: 7.867

7.  Neisseria gonorrhoeae uses cellular proteins CXCL10 and IL8 to enhance HIV-1 transmission across cervical mucosa.

Authors:  Anwesha Sanyal; Chengli Shen; Ming Ding; Todd A Reinhart; Yue Chen; Soni Sankapal; Phalguni Gupta
Journal:  Am J Reprod Immunol       Date:  2019-04-11       Impact factor: 3.886

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.